Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
TARIS, a biopharmaceutical company developing transformational therapies to treat people with debilitating urological disorders, today announced positive preliminary safety and efficacy data from its clinical study of TAR-302 for the treatment of patients with idiopathic overactive bladder (OAB) refractory to oral therapy. Subjects in the Phase 1b study received a single TAR-302 system, which provides continuous local dosing of the approved antimuscarinic agent trospium into the bladder. Subjects who were experiencing an average of more than five daily urge incontinence episodes demonstrated a reduction in mean daily episodes of 75% following dosing for 42 days (p=0.0049). Based on the unmet need in this disease state and the efficacy demonstrated in this study on established endpoints, TARIS plans to rapidly advance this program into later stage trials. “The results of this study suggest TAR-302 may come to represent an innovative new approach to treating overactive bladder,” said Michael J. Kennelly, M.D., FACS, Professor of Urology at Carolinas Medical Center, Medical Director of the Charlotte Continence Center and Women’s Center of Pelvic Heath, and Principal Investigator of the TAR-302 clinical studies. “There is a substantial need for alternative options in the management of OAB when patients fail oral therapies. The compelling efficacy observed to date with TAR-302, in the absence of side-effects, represents a potentially significant advance in the development of improved therapies for these patients.” Read more.
Source: PRNewswire, August 28, 2018
The 10 charities, including Alzheimer’s Society, Age UK, Marie Curie, warned that the taboo around the topic forces those affected to struggle in silence and more research is needed. As a result, the organisations held a workshop where common problems and solutions for incontinence issues were discussed by patients, carers, researchers and clinicians. Others involved include Parkinson’s UK, Guts UK, the Urology Foundation, Devices for Dignity, the National Institute for Health Research, and the James Lind Alliance. A report based on the meeting – titled My bladder and bowel own my life and published today – recommends tackling the stigma and funding research into the issue. Read more.
Source: Nursing Times, August 22, 2018
Patients with spinal cord injuries report that in addition to paralysis the lack of bladder control is one of the most troubling issues. At University of California Los Angeles, researchers have shown that they were able to restore significant bladder control to five men that suffered through spinal cord injuries years prior to treatment. The researchers used transcutaneous magnetic spinal cord stimulation as their technique, delivering pulses of focused magnetic fields to the site of the injuries. Similar technology was just cleared in the United States to treat obsessive compulsive disorder. Read more.
Source: Medgadget, August 22, 2018
Recommendation on screening for urinary incontinence in women by the Women’s Preventive Services Initiative (WPSI), a national coalition of women’s health professional organizations and patient representatives. The WPSI’s recommendations are intended to guide clinical practice and coverage of services for the Health Resources and Services Administration and other stakeholders. The target audience for this recommendation includes all clinicians providing preventive health care for women, particularly in primary care settings. This recommendation applies to women of all ages, as well as adolescents. Read more.
Source: Annals of Internal Medicine, August 14, 2018
Urinary incontinence occurs in nearly 1 in 2 women aged 45 years and older, a new study suggests. The study examined survey results from 143,096 women at baseline (2006–2009) and 59,060 women who participated in a follow-up survey (2012–2015). The prevalence of urinary leakage reported in these surveys was 44% and 44.6%, respectively, Kristine Concepcion, MD, MPH, of Family Planning NSW Ashfield in New South Wales, Australia, and colleagues reported in Neurourology and Urodynamics. Read more.
Source: Renal and Urology News, August 2, 2018
Procedures marketed to improve a woman’s “intimate health” using lasers or ultrasound are not only unapproved, but are also causing burns and other painful damage, the Food and Drug Administration said Monday. The FDA has warned seven companies that are promoting their devices for these procedures, and issued a general alert for patients and doctors. The agency has also warned the public against asking for such procedures. The laser and ultrasound equipment used in these unapproved procedures has FDA approval for removing genital warts, other growths and in operations such as hysterectomies. But they have not been shown to tighten up muscles, increase sexual pleasure or relieve pain during intercourse, the FDA said. Read more.
Source: NBC News, July 30, 2018
Today’s healthcare is full of technology that would seem like science fiction to our grandparents. But this is far from true in every area: some remain woefully neglected by innovation. Hop in a time machine back to ancient Egypt and you would find recognisable examples of the absorbent pads and catheters which are still a mainstay in the management of incontinence today. The earliest known reference to an absorbent pad dates from 4th-century Egypt: the female scientist Hypatia is recorded as having thrown her menstrual rag at a student to ward off his infatuation with her. The pad remained a homemade “product” for many centuries until the 19th century, when manufactured versions of reuseable “antiseptic cotton for absorbing discharges” could be purchased from pharmacies. Disposable pads, first produced by Kotex in 1920, were in widespread use by the late 1930s. Since then, the only major innovation in their design has been the introduction of super absorbent polymers in the 1980s, which have dramatically improved absorbency. Read more.
Source: The Conversation, July 30, 2018